Melanoma DNA vaccine - MannKind Corporation
Latest Information Update: 24 Oct 2021
At a glance
- Originator CTL ImmunoTherapies Corporation
- Class Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 19 Nov 2003 Discontinued - Phase-I for Malignant melanoma in USA (Intralymphatic)
- 15 Jun 2001 Phase-I clinical trials for Malignant melanoma in USA (Intralymphatic)